Tag: Phase 3 Clinical Trials

J&J’s Icotyde improved joint disease activity versus placebo in the Phase 3 ICONIC-PsA 1 trial. The results support potential expansion beyond plaque psoriasis, although its use in psoriatic arthritis remains investigational.